Foselutoclax (UBX1325) is a senolytic small-molecule inhibitor of BCL-xL. UBX1325 is a phosphate pro-drug with improved aqueous solubility that releases the active parent molecule UBX0601. UBX0601 prevented the formation of the antiapoptotic protein complexes through binding of BCL-xL and BCL-2 in biochemical competition binding assays with pKi of 8.6. UBX0601 demonstrated potent target engagement (TE) through inhibition of the BCL-xL and BIM interaction. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR).
